Andrew Azman

List of Publications by Year
in descending order

132 papers	12,647 citations	81743 39 h-index	33814 99 g-index
177 all docs	177 docs citations	177 times ranked	22192 citing authors

#	Article	IF	Citations
1	Risk of Reinfection After Seroconversion to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): A Population-based Propensity-score Matched Cohort Study. Clinical Infectious Diseases, 2022, 74, 622-629.	2.9	61
2	Neutralizing Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants Induced by Natural Infection or Vaccination: A Systematic Review and Pooled Analysis. Clinical Infectious Diseases, 2022, 74, 734-742.	2.9	88
3	Seroprevalence of anti-SARS-CoV-2 IgG antibodies, risk factors for infection and associated symptoms in Geneva, Switzerland: a population-based study. Scandinavian Journal of Public Health, 2022, 50, 124-135.	1.2	22
4	Combining antibody markers for serosurveillance of SARS-CoV-2 to estimate seroprevalence and time-since-infection. Epidemiology and Infection, 2022, 150, e20.	1.0	1
5	SARS-CoV-2 Seroprevalence before Delta Variant Surge, Chattogram, Bangladesh, Marchâ€“June 2021. Emerging Infectious Diseases, 2022, 28, 429-431.	2.0	13
6	Specchio-COVID19 cohort study: a longitudinal follow-up of SARS-CoV-2 serosurvey participants in the canton of Geneva, Switzerland. BMJ Open, 2022, 12, e055515.	0.8	12
7	Global landscape of SARS-CoV-2 genomic surveillance and data sharing. Nature Genetics, 2022, 54, 499-507.	9.4	138
8	Global diversity of policy, coverage, and demand of COVID-19 vaccines: a descriptive study. BMC Medicine, 2022, 20, 130.	2.3	26
9	Cholera. Lancet, The, 2022, 399, 1429-1440.	6.3	69
10	Association between SARS-CoV-2 Seroprevalence in Nursing Home Staff and Resident COVID-19 Cases and Mortality: A Cross-Sectional Study. Viruses, 2022, 14, 43.	1.5	6
11	Occupational risk of SARS-CoV-2 infection and reinfection during the second pandemic surge: a cohort study. Occupational and Environmental Medicine, 2022, 79, 116-119.	1.3	7
12	In-person schooling and associated COVID-19 risk in the United States over spring semester 2021. Science Advances, 2022, 8, eabm9128.	4.7	10
13	A SARS-CoV-2 omicron (B.1.1.529) variant outbreak in a primary school in Geneva, Switzerland. Lancet Infectious Diseases, The, 2022, 22, 767-768.	4.6	16
14	SARS-CoV-2 Antibody Prevalence and Population-Based Death Rates, Greater Omdurman, Sudan. Emerging Infectious Diseases, 2022, 28, 1026-1030.	2.0	10
15	The seasonality of cholera in sub-Saharan Africa: a statistical modelling study. The Lancet Global Health, 2022, 10, e831-e839.	2.9	11
16	Applying mixture model methods to SARS-CoV-2 serosurvey data from Geneva. Epidemics, 2022, 39, 100572.	1.5	2
17	Cholera outbreaks in sub-Saharan Africa during 2010-2019: a descriptive analysis. International Journal of Infectious Diseases, 2022, 122, 215-221.	1.5	13
18	Serology-informed estimates of SARS-CoV-2 infection fatality risk in Geneva, Switzerland. Lancet Infectious Diseases, The, 2021, 21, e69-e70.	4.6	135

#	Article	IF	Citations
19	Highly targeted spatiotemporal interventions against cholera epidemics, 2000â€“19: a scoping review. Lancet Infectious Diseases, The, 2021, 21, e37-e48.	4.6	19
20	Age-specific mortality and immunity patterns of SARS-CoV-2. Nature, 2021, 590, 140-145.	13.7	883
21	Insight into the practical performance of RT-PCR testing for SARS-CoV-2 using serological data: a cohort study. Lancet Microbe, The, 2021, 2, e79-e87.	3.4	67
22	Household COVID-19 risk and in-person schooling. Science, 2021, 372, 1092-1097.	6.0	162
23	Setting a Course for Preventing Hepatitis E in Low and Lower-Middle-Income Countries: A Systematic Review of Burden and Risk Factors. Open Forum Infectious Diseases, 2021, 8, ofab178.	0.4	5
24	Seroprevalence of anti-SARS-CoV-2 antibodies after the second pandemic peak. Lancet Infectious Diseases, The, 2021, 21, 600-601.	4.6	59
25	Serological evidence of human infection with SARS-CoV-2: a systematic review and meta-analysis. The Lancet Global Health, 2021, 9, e598-e609.	2.9	193
26	Insights into household transmission of SARS-CoV-2 from a population-based serological survey. Nature Communications, 2021, 12, 3643.	5.8	61
27	Regional sequencing collaboration reveals persistence of the T12 Vibrio cholerae O1 lineage in West Africa. ELife, 2021, 10, .	2.8	6
28	Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 IgG in Juba, South Sudan, 20201. Emerging Infectious Diseases, 2021, 27, 1598-1606.	2.0	38
29	Large variation in anti-SARS-CoV-2 antibody prevalence among essential workers in Geneva, Switzerland. Nature Communications, 2021, 12, 3455.	5.8	30
30	Persistence of anti-SARS-CoV-2 antibodies: immunoassay heterogeneity and implications for serosurveillance. Clinical Microbiology and Infection, 2021, 27, 1695.e7-1695.e12.	2.8	38
31	Clinical Cholera Surveillance Sensitivity in Bangladesh and Implications for Large-Scale Disease Control. Journal of Infectious Diseases, 2021, 224, S725-S731.	1.9	2
32	Hepatitis E in Bangladesh: Insights From a National Serosurvey. Journal of Infectious Diseases, 2021, 224, S805-S812.	1.9	11
33	A Novel Luminescence-Based Serum Bactericidal Assay for Vibrio cholerae Reduces Assay Variation, Is Time- and Cost-Effective, and Directly Measures Continuous Titer Values. American Journal of Tropical Medicine and Hygiene, 2021, 105, 622-626.	0.6	0
34	Moving forward with an imperfect vaccine. Lancet Infectious Diseases, The, 2021, 21, 1339-1341.	4.6	4
35	Towards global control of parasitic diseases in the Covid-19 era: One Health and the future of multisectoral global health governance. Advances in Parasitology, 2021, 114, 1-26.	1.4	12
36	A public health strategy for SARS-CoV-2, grounded in science, should guide Swiss schools through the coming winter. Swiss Medical Weekly, 2021, 151, w30086.	0.8	1

#	Article	IF	Citations
37	Seroprevalence of anti-SARS-CoV-2 antibodies 6 months into the vaccination campaign in Geneva, Switzerland, 1 June to 7 July 2021. Eurosurveillance, 2021, 26, .	3.9	44
38	Putting cholera rapid tests to work in surveillance and control of cholera. Clinical Microbiology and Infection, 2021, , .	2.8	0
39	Seroprevalence of SARS-CoV-2 antibodies and retrospective mortality in a refugee camp, Dagahaley, Kenya. PLoS ONE, 2021, 16, e0260989.	1.1	10
40	Case-area targeted preventive interventions to interrupt cholera transmission: Current implementation practices and lessons learned. PLoS Neglected Tropical Diseases, 2021, 15, e0010042.	1.3	10
41	Clinical and Epidemiological Aspects of Diphtheria: A Systematic Review and Pooled Analysis. Clinical Infectious Diseases, 2020, 71, 89-97.	2.9	76
42	Surveillance and the global fight against cholera: Setting priorities and tracking progress. Vaccine, 2020, 38, A28-A30.	1.7	12
43	Epidemiology of Cholera in Bangladesh: Findings From Nationwide Hospital-based Surveillance, 2014â€“2018. Clinical Infectious Diseases, 2020, 71, 1635-1642.	2.9	28
44	Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients. Science Immunology, 2020, 5, .	5.6	561
45	From China: hope and lessons for COVID-19 control. Lancet Infectious Diseases, The, 2020, 20, 756-757.	4.6	54
46	The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. Annals of Internal Medicine, 2020, 172, 577-582.	2.0	4,808
47	Achieving coordinated national immunity and cholera elimination in Haiti through vaccination: a modelling study. The Lancet Global Health, 2020, 8, e1081-e1089.	2.9	26
48	HIT-COVID, a global database tracking public health interventions to COVID-19. Scientific Data, 2020, 7, 286.	2.4	76
49	Mapping geographical inequalities in access to drinking water and sanitation facilities in low-income and middle-income countries, 2000â€“17. The Lancet Global Health, 2020, 8, e1162-e1185.	2.9	91
50	Field Evaluation of Cholkit Rapid Diagnostic Test forVibrio Cholerae O1During a Cholera Outbreak in Malawi, 2018. Open Forum Infectious Diseases, 2020, 7, ofaa493.	0.4	5
51	Cholera in Haiti â€“ Authors' reply. The Lancet Global Health, 2020, 8, e1470-e1471.	2.9	0
52	Serology for SARS-CoV-2: Apprehensions, opportunities, and the path forward. Science Immunology, 2020, 5, .	5.6	138
53	Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. Lancet, The, 2020, 396, 313-319.	6.3	919
54	The potential impact of COVID-19 in refugee camps in Bangladesh and beyond:Â A modeling study. PLoS Medicine, 2020, 17, e1003144.	3.9	112

#	Article	IF	Citations
55	Sero-evaluation of Immune Responses to Vibrio cholerae in a Postelimination Setting. Open Forum Infectious Diseases, 2020, 7, ofaa136.	0.4	0
56	Alternative observational designs to estimate the effectiveness of one dose of oral cholera vaccine in Lusaka, Zambia. Epidemiology and Infection, 2020, 148, e78.	1.0	6
57	Socioeconomically Disadvantaged Neighborhoods Face Increased Persistence of SARS-CoV-2 Clusters. Frontiers in Public Health, 2020, 8, 626090.	1.3	23
58	Vibrio cholerae O1 transmission in Bangladesh: insights from a nationally representative serosurvey. Lancet Microbe, The, 2020, 1, e336-e343.	3.4	27
59	Assessing the impact of non-pharmaceutical interventions on SARS-CoV-2 transmission in Switzerland. Swiss Medical Weekly, 2020, 150, w20295.	0.8	61
60	Successive epidemic waves of cholera in South Sudan between 2014 and 2017: a descriptive epidemiological study. Lancet Planetary Health, The, 2020, 4, e577-e587.	5.1	18
61	Hepatitis E should be considered a neglected tropical disease. PLoS Neglected Tropical Diseases, 2019, 13, e0007453.	1.3	17
62	Cholera prevention and control in refugee settings: Successes and continued challenges. PLoS Neglected Tropical Diseases, 2019, 13, e0007347.	1.3	37
63	Measles and the canonical path to elimination. Science, 2019, 364, 584-587.	6.0	35
64	Estimating cholera incidence with cross-sectional serology. Science Translational Medicine, 2019, 11, .	5.8	50
65	The inverse relationship between national food security and annual cholera incidence: a 30-country analysis. BMJ Global Health, 2019, 4, e001755.	2.0	10
66	Immune responses to O-specific polysaccharide (OSP) in North American adults infected with Vibrio cholerae O1 Inaba. PLoS Neglected Tropical Diseases, 2019, 13, e0007874.	1.3	13
67	Projected population-wide impact of antiretroviral therapy-linked isoniazid preventive therapy in a high-burden setting. Aids, 2019, 33, 525-536.	1.0	7
68	The projected impact of geographic targeting of oral cholera vaccination in sub-Saharan Africa: A modeling study. PLoS Medicine, 2019, 16, e1003003.	3.9	23
69	Genomic insights into the 2016â€“2017 cholera epidemic in Yemen. Nature, 2019, 565, 230-233.	13.7	129
70	Mitigating Cholera in the Aftermath of Cyclone Idai. American Journal of Tropical Medicine and Hygiene, 2019, 101, 960-962.	0.6	12
71	Mapping the burden of cholera in sub-Saharan Africa and implications for control: an analysis of data across geographical scales. Lancet, The, 2018, 391, 1908-1915.	6.3	133
72	Immunogenicity and Protection From a Single Dose of Internationally Available Killed Oral Cholera Vaccine: A Systematic Review and Metaanalysis. Clinical Infectious Diseases, 2018, 66, 1960-1971.	2.9	21

#	Article	IF	Citations
73	Single-Dose Cholera Vaccine in Response to an Outbreak in Zambia. New England Journal of Medicine, 2018, 378, 577-579.	13.9	49
74	Oral cholera vaccine in cholera prevention and control, Malawi. Bulletin of the World Health Organization, 2018, 96, 428-435.	1.5	19
75	Cholera Epidemic in South Sudan and Uganda and Need for International Collaboration in Cholera Control. Emerging Infectious Diseases, 2018, 24, 883-887.	2.0	12
76	Progress and Challenges in Using Oral Cholera Vaccines to Control Outbreaks: The MÃ©decins Sans FrontiÃ¨res Experience. Journal of Infectious Diseases, 2018, 218, S165-S166.	1.9	6
77	The Epidemiology of Cholera in Zanzibar: Implications for the Zanzibar Comprehensive Cholera Elimination Plan. Journal of Infectious Diseases, 2018, 218, S173-S180.	1.9	10
78	Cholera epidemic in Yemen â€“ Author's reply. The Lancet Global Health, 2018, 6, e1284-e1285.	2.9	0
79	A Multisectoral Emergency Response Approach to a Cholera Outbreak in Zambia: October 2017â€“February 2018. Journal of Infectious Diseases, 2018, 218, S181-S183.	1.9	11
80	The incubation period of hepatitis E genotype 1: insights from pooled analyses of travellers. Epidemiology and Infection, 2018, 146, 1533-1536.	1.0	5
81	Micro-Hotspots of Risk in Urban Cholera Epidemics. Journal of Infectious Diseases, 2018, 218, 1164-1168.	1.9	28
82	Cholera epidemic in Yemen, 2016â€“18: an analysis of surveillance data. The Lancet Global Health, 2018, 6, e680-e690.	2.9	203
83	Near real-time forecasting for cholera decision making in Haiti after Hurricane Matthew. PLoS Computational Biology, 2018, 14, e1006127.	1.5	27
84	Evaluation of the <scp>SD</scp> bioline cholera rapid diagnostic test during the 2016 cholera outbreak in Lusaka, Zambia. Tropical Medicine and International Health, 2018, 23, 834-840.	1.0	16
85	The potential impact of case-area targeted interventions in response to cholera outbreaks: A modeling study. PLoS Medicine, 2018, 15, e1002509.	3.9	52
86	Dried Blood Spots for Measuring Vibrio cholerae-specific Immune Responses. PLoS Neglected Tropical Diseases, 2018, 12, e0006196.	1.3	19
87	Prolonging herd immunity to cholera via vaccination: Accounting for human mobility and waning vaccine effects. PLoS Neglected Tropical Diseases, 2018, 12, e0006257.	1.3	14
88	High Prevalence of Shigella or Enteroinvasive Escherichia coli Carriage among Residents of an Internally Displaced Persons Camp in South Sudan. American Journal of Tropical Medicine and Hygiene, 2018, 98, 595-597.	0.6	3
89	Adapting to the global shortage of cholera vaccines: targeted single dose cholera vaccine in response to an outbreak in South Sudan. Lancet Infectious Diseases, The, 2017, 17, e123-e127.	4.6	35
90	El NiÃ±o and the shifting geography of cholera in Africa. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 4436-4441.	3.3	68

#	Article	IF	Citations
91	Vaccination against cholera in Juba â€“ Authors' reply. Lancet Infectious Diseases, The, 2017, 17, 480-481.	4.6	2
92	Safety of a killed oral cholera vaccine (Shanchol) in pregnant women in Malawi: an observational cohort study. Lancet Infectious Diseases, The, 2017, 17, 538-544.	4.6	22
93	Cholera outbreak in Yemen. The Lancet Gastroenterology and Hepatology, 2017, 2, 777.	3.7	6
94	Protection against cholera from killed whole-cell oral cholera vaccines: a systematic review and meta-analysis. Lancet Infectious Diseases, The, 2017, 17, 1080-1088.	4.6	138
95	Current and future trends in tuberculosis incidence in New York City: a dynamic modelling analysis. Lancet Public Health, The, 2017, 2, e323-e330.	4.7	12
96	The importance of thinking beyond the water-supply in cholera epidemics: A historical urban case-study. PLoS Neglected Tropical Diseases, 2017, 11, e0006103.	1.3	13
97	Neighborhood-targeted and case-triggered use of a single dose of oral cholera vaccine in an urban setting: Feasibility and vaccine coverage. PLoS Neglected Tropical Diseases, 2017, 11, e0005652.	1.3	26
98	MDR-TB treatment as prevention: The projected population-level impact of expanded treatment for multidrug-resistant tuberculosis. PLoS ONE, 2017, 12, e0172748.	1.1	30
99	What is a Hotspot Anyway?. American Journal of Tropical Medicine and Hygiene, 2017, 96, 1270-1273.	0.6	79
100	High Hepatitis E Seroprevalence Among Displaced Persons in South Sudan. American Journal of Tropical Medicine and Hygiene, 2017, 96, 1296-1301.	0.6	19
101	Population-Level Effect of Cholera Vaccine on Displaced Populations, South Sudan, 2014. Emerging Infectious Diseases, 2016, 22, 1067-1070.	2.0	29
102	Cholera Rapid Test with Enrichment Step Has Diagnostic Performance Equivalent to Culture. PLoS ONE, 2016, 11, e0168257.	1.1	37
103	Immune Responses to an Oral Cholera Vaccine in Internally Displaced Persons in South Sudan. Scientific Reports, 2016, 6, 35742.	1.6	22
104	Feasibility of achieving the 2025 WHO global tuberculosis targets in South Africa, China, and India: a combined analysis of 11 mathematical models. The Lancet Global Health, 2016, 4, e806-e815.	2.9	138
105	Cost-effectiveness and resource implications of aggressive action on tuberculosis in China, India, and South Africa: a combined analysis of nine models. The Lancet Global Health, 2016, 4, e816-e826.	2.9	69
106	Trends in the Mechanistic and Dynamic Modeling of Infectious Diseases. Current Epidemiology Reports, 2016, 3, 212-222.	1.1	27
107	Single-Dose Oral Cholera Vaccine in Bangladesh. New England Journal of Medicine, 2016, 375, e12.	13.9	5
108	How social structures, space, and behaviors shape the spread of infectious diseases using chikungunya as a case study. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 13420-13425.	3.3	100

#	Article	IF	Citations
109	Effectiveness of one dose of oral cholera vaccine in response to an outbreak: a case-cohort study. The Lancet Global Health, 2016, 4, e856-e863.	2.9	114
110	Cholera cases cluster in time and space in Matlab, Bangladesh: implications for targeted preventive interventions. International Journal of Epidemiology, 2016, 45, dyw267.	0.9	37
111	Comparison of inferred relatedness based on multilocus variable-number tandem-repeat analysis and whole genome sequencing ofVibrio choleraeO1. FEMS Microbiology Letters, 2016, 363, fnw116.	0.7	19
112	Safe water, sanitation, hygiene, and a cholera vaccine. Lancet, The, 2016, 387, 28.	6.3	22
113	Effect of Artesunateâ€“Amodiaquine on Mortality Related to Ebola Virus Disease. New England Journal of Medicine, 2016, 374, 23-32.	13.9	111
114	Dengue Virus (DENV) Neutralizing Antibody Kinetics in Children After Symptomatic Primary and Postprimary DENV Infection. Journal of Infectious Diseases, 2016, 213, 1428-1435.	1.9	36
115	Micro-scale Spatial Clustering of Cholera Risk Factors in Urban Bangladesh. PLoS Neglected Tropical Diseases, 2016, 10, e0004400.	1.3	17
116	The First Use of the Global Oral Cholera Vaccine Emergency Stockpile: Lessons from South Sudan. PLoS Medicine, 2015, 12, e1001901.	3.9	65
117	Tracking Cholera through Surveillance of Oral Rehydration Solution Sales at Pharmacies: Insights from Urban Bangladesh. PLoS Neglected Tropical Diseases, 2015, 9, e0004230.	1.3	16
118	A Novel Tool Improves Existing Estimates of Recent Tuberculosis Transmission in Settings of Sparse Data Collection. PLoS ONE, 2015, 10, e0144137.	1.1	7
119	Reactive vaccination in the presence of disease hotspots. Proceedings of the Royal Society B: Biological Sciences, 2015, 282, 20141341.	1.2	30
120	Outbreaks of cholera in the time of Ebola: pre-emptive action needed. Lancet, The, 2015, 385, 851.	6.3	7
121	The Impact of a One-Dose versus Two-Dose Oral Cholera Vaccine Regimen in Outbreak Settings: A Modeling Study. PLoS Medicine, 2015, 12, e1001867.	3.9	87
122	How much is tuberculosis screening worth? Estimating the value of active case finding for tuberculosis in South Africa, China, and India. BMC Medicine, 2014, 12, 216.	2.3	77
123	Genetic Variation ofVibrio choleraeduring Outbreaks, Bangladesh, 2010â€“2011. Emerging Infectious Diseases, 2014, 20, 54-60.	2.0	20
124	Bold thinking for bold results: modeling the elimination of tuberculosis. International Journal of Tuberculosis and Lung Disease, 2014, 18, 883-883.	0.6	1
125	Sedation Depth During Spinal Anesthesia and Survival in Elderly Patients Undergoing Hip Fracture Repair. Anesthesia and Analgesia, 2014, 118, 977-980.	1.1	73
126	Transforming the Fight Against Tuberculosis: Targeting Catalysts of Transmission. Clinical Infectious Diseases, 2014, 59, 1123-1129.	2.9	37

#	Article	IF	Citations
127	Evaluation of enrichment method for the detection of <scp>V</scp>ibrio cholerae <scp>O</scp>1 using a rapid dipstick test in <scp>B</scp>angladesh. Tropical Medicine and International Health, 2014, 19, 301-307.	1.0	39
128	Epidemic Risk from Cholera Introductions into Mexico. PLOS Currents, 2014, 6, .	1.4	13
129	Household transmission of influenza A and B in a school-based study of non-pharmaceutical interventions. Epidemics, 2013, 5, 181-186.	1.5	18
130	The incubation period of cholera: A systematic review. Journal of Infection, 2013, 66, 432-438.	1.7	134
131	Population-Level Impact of Active Tuberculosis Case Finding in an Asian Megacity. PLoS ONE, 2013, 8, e77517.	1.1	28
132	Urban Cholera Transmission Hotspots and Their Implications for Reactive Vaccination: Evidence from Bissau City, Guinea Bissau. PLoS Neglected Tropical Diseases, 2012, 6, e1901.	1.3	51